newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS
  • Aligos Therapeutics, Inc. granted non-qualified stock options to newly hired employees on October 15, 2025.
  • The Inducement Grant covers an aggregate of 27,400 shares of the company's stock.
  • The grants were issued under the 2024 Inducement Plan to comply with Nasdaq Listing Rule 5635(c)(4).
  • The exercise price per share equals the closing price of Aligos' common stock on the grant date.
  • Shares will vest over a four-year period, with 25% vesting on the first anniversary of the grant date & the remainder vesting in equal monthly installments.
  • Vesting is subject to the continued employment of the recipients through applicable vesting dates.
  • Aligos is a clinical stage biopharmaceutical company developing therapies for liver and viral diseases, including chronic hepatitis B, MASH, & coronaviruses.